Trials / Not Yet Recruiting
Not Yet RecruitingNCT05963087
Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer
Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer: a Prospective, Exploratory, Phase II Clinical Study
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy and safety of Cetuximab in combination with dabrafenib and Tislelizumab in BRAF mutated treatment of advanced colorectal cancer
Detailed description
Due to Encorafenib has not been marketed in China, it is difficult to benefit patients, and there are no reported studies of Dabrafenib, also a BRAF inhibitor, in combination with anti-EGFR monoclonal antibody and immunotherapy in BRAF mutated mCRC. Therefore, we intend to use Dabrafenib in combination with cetuximab and Tislelizumab in the treatment of BRAF V600E mutated patients with advanced colorectal cancer to observe the initial efficacy and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetuximab Dabrafenib Tislelizumab | Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2025-02-01
- Completion
- 2026-06-01
- First posted
- 2023-07-27
- Last updated
- 2023-07-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05963087. Inclusion in this directory is not an endorsement.